Last reviewed · How we verify
releasing hormone agonist therapy
Releasing hormone agonist therapy works by mimicking the action of natural hormones to stimulate the release of other hormones.
Releasing hormone agonist therapy works by mimicking the action of natural hormones to stimulate the release of other hormones. Used for Prostate cancer, Breast cancer.
At a glance
| Generic name | releasing hormone agonist therapy |
|---|---|
| Sponsor | Cancer Research UK |
| Drug class | Releasing hormone agonist |
| Target | Gonadotropin-releasing hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This type of therapy is used to treat various conditions by manipulating hormone levels in the body. The exact mechanism can vary depending on the specific hormone being targeted.
Approved indications
- Prostate cancer
- Breast cancer
Common side effects
- Hot flashes
- Nausea
- Vomiting
Key clinical trials
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity (NA)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Body Composition Assessment in Transgender Population.
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) (PHASE2)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- releasing hormone agonist therapy CI brief — competitive landscape report
- releasing hormone agonist therapy updates RSS · CI watch RSS
- Cancer Research UK portfolio CI